Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST-STEP: Stalevo vs Carbidopa/Levodopa in Early Parkinson's Disease
NCT00134966Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of levodopa in Parkinson's disease (PD) (2 arms), sponsored by Novartis. Primary endpoint: Unified Parkinson's Disease Rating Scale Parts II and III Total Score at 39 weeks. Started Aug 2005; status: completed.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00134966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00134966.